Olivier Huillard

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 93 publications

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 26, 2026

Correction: Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.

Correction: Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.

Journal: British journal of cancer

Published: January 20, 2026

Genomic characterization of aggressiveness in pituitary neuroendocrine tumors.

Genomic characterization of aggressiveness in pituitary neuroendocrine tumors.

Journal: Neuro-oncology

Published: January 15, 2026

Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.

Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.

Journal: Cancer immunology, immunotherapy : CII

Published: December 11, 2025

Belzutifan for Advanced Pheochromocytoma or Paraganglioma.

Belzutifan for Advanced Pheochromocytoma or Paraganglioma.

Journal: The New England journal of medicine

Published: October 22, 2025

Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell Carcinoma.

Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell Carcinoma.

Journal: Clinical genitourinary cancer

Published: October 09, 2025

Predisposition to prostate cancer and clinical implications in a real-life cohort.

Predisposition to prostate cancer and clinical implications in a real-life cohort.

Journal: European journal of human genetics : EJHG

Published: November 05, 2024

Resting energy expenditure as a predictor of immune checkpoint inhibitors response in older patients with non-small cell metastatic lung cancer: A pooled analysis of two prospective cohort studies.

Resting energy expenditure as a predictor of immune checkpoint inhibitors response in older patients with non-small cell metastatic lung cancer: A pooled analysis of two prospective cohort studies.

Journal: Clinical nutrition (Edinburgh, Scotland)

Published: September 02, 2024

Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial.

Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial.

Journal: Clinical pharmacokinetics

Published: June 13, 2024

Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial.

Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial.

Journal: Clinical genitourinary cancer

Published: May 17, 2024

Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial.

Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial.

Journal: European urology oncology

Published: April 12, 2024

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 13, 2023

Showing 1-12 of 93

Last Updated: 09/26/2026